Sisram Medical Ltd. (HK:1696)
:1696
Want to see HK:1696 full AI Analyst Report?
1696 Stock Chart & Stats
HK$3.87
-HK$0.01(-0.28%)
At close: 4:00 PM EST
HK$3.87
-HK$0.01(-0.28%)
Day’s Range― - ―
52-Week RangeHK$2.70 - HK$8.07
Previous CloseN/A
Volume75.47K
Average Volume (3M)469.37K
Market Cap
HK$1.31B
Enterprise ValueHK$151.19M
Total Cash (Recent Filing)HK$62.01M
Total Debt (Recent Filing)HK$46.97M
Price to Earnings (P/E)5.0
Beta1.14
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.82%
Share Statistics
EPS (TTM)0.04
Shares Outstanding468,343,080
10 Day Avg. Volume515,040
30 Day Avg. Volume469,367
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)0.53
Price to Sales (P/S)0.69
P/FCF Ratio37.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.50Price Target Upside16.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.48
Revenue Forecast (FY)HK$3.22B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and an expanding equity base give Sisram durable financial flexibility to fund product development, maintain service networks and absorb demand cycles typical in medical devices. This reduces refinancing risk and supports strategic investments without stressing cash flows.
Recurring Consumables And Service RevenueA business model built on capital equipment plus consumables and service creates annuity-like revenue from an installed base. That recurring mix smooths top-line volatility, improves customer stickiness, and supports long-term cash generation independent of new unit sales.
Strong Gross Margins (~59%)High gross margins indicate product differentiation or pricing power in energy-based aesthetic devices. Sustained gross profitability provides room to absorb SG&A and R&D, enabling reinvestment and margin recovery even if operating costs remain elevated.
Bears Say
Net Margin CompressionA decline from double-digit to low single-digit net margins suggests persistent margin pressure from pricing competition or higher operating costs. That erosion limits free cash flow conversion and the company's ability to fund growth initiatives, dividends, or buybacks sustainably.
Weakened Cash GenerationSharp decline in operating and free cash flow signals weaker cash conversion, possibly from working-capital swings or higher investments. Reduced cash generation constrains reinvestment in R&D and service infrastructure and increases reliance on the balance sheet for funding needs.
Earnings Deterioration (EPS Decline)A large negative EPS growth rate reflects meaningful earnings deterioration, which can weaken internal funding capacity and investor confidence. Persistent EPS declines make sustaining dividends, R&D spend and margin recovery more challenging absent operational fixes.
Sisram Medical Ltd. News
1696 FAQ
What was Sisram Medical Ltd.’s price range in the past 12 months?
Sisram Medical Ltd. lowest stock price was HK$2.70 and its highest was HK$8.07 in the past 12 months.
What is Sisram Medical Ltd.’s market cap?
Sisram Medical Ltd.’s market cap is HK$1.31B.
When is Sisram Medical Ltd.’s upcoming earnings report date?
Sisram Medical Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 95 days.
How were Sisram Medical Ltd.’s earnings last quarter?
Sisram Medical Ltd. released its earnings results on Mar 23, 2026. The company reported HK$0.21 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.21.
Is Sisram Medical Ltd. overvalued?
According to Wall Street analysts Sisram Medical Ltd.’s price is currently Undervalued.
Does Sisram Medical Ltd. pay dividends?
Sisram Medical Ltd. pays a Annually dividend of HK$0.126 which represents an annual dividend yield of 2.82%. See more information on Sisram Medical Ltd. dividends here
What is Sisram Medical Ltd.’s EPS estimate?
Sisram Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sisram Medical Ltd. have?
Sisram Medical Ltd. has 468,343,080 shares outstanding.
What happened to Sisram Medical Ltd.’s price movement after its last earnings report?
Sisram Medical Ltd. reported an EPS of HK$0.21 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -6.316%.
Which hedge fund is a major shareholder of Sisram Medical Ltd.?
Currently, no hedge funds are holding shares in HK:1696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sisram Medical Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.21%
12-Months-Change
Fundamentals
Return on Equity
4.02%
Trailing 12-Months
Asset Growth
2.43%
Trailing 12-Months
Company Description
Sisram Medical Ltd.
Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical, minimally invasive treatment systems, and non-energy based devices and cosmeceuticals in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers products and treatments portfolio, including hair removal, skin rejuvenation, acne and acne scars, body and face contouring, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodelling injectables, personal care, aesthetic dentistry, trans epidermal delivery, cellulite treatment, stretch marks, vascular and pigmented lesions, hydradermabrasion, blepharoplasty-non surgical eyelid lift, liposuction, feminine health, and sexual rehabilitation. The company manufactures, distributes, and sells medical equipment. It offers its products under the Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT brands. Sisram Medical Ltd was incorporated in 2013 and is headquartered in Caesarea, Israel.
1696 Stock 12 Month Forecast
Average Price Target
HK$4.50
▲(16.28% Upside)
Technical Analysis
Peijia Medical Ltd.
―
Yestar Healthcare Holdings Co Ltd
―
Gaush Meditech Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―
Austar Lifesciences Ltd.
―
Options Prices
Currently, No data available
---